GlassScriptPhysician profile
Nancy N Nagle
NPI 1740245745
$51,283.71
in general payments reported to CMS, 2019-2025
32 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,093 · 2020: $2,357 · 2021: $389 · 2022: $129 · 2023: $14.59 · 2024: $20K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Travel and Lodging: $962 · Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,400.00 |
| Travel and Lodging | $962.16 |
| Food and Beverage | $955.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $46,111.95 | 2019-2025 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $920.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $700.01 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $514.94 | 2019-2020 | |
| Genentech USA, INC. | $448.25 | 2019-2021 | |
| Philips North America LLC | $258.19 | 2019-2021 | |
| Grifols USA, LLC | $248.93 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $222.97 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $190.21 | 2019-2020 | |
| Mylan Specialty L.P. | $171.17 | 2019-2020 | |
| Genzyme Corporation | $170.37 | 2019-2020 | |
| Shire North American Group INC | $168.23 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $134.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $117.96 | 2019-2021 | |
| Circassia INC. | $84.81 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $84.05 | 2020 | |
| Gilead Sciences, INC. | $81.21 | 2021-2023 | |
| Insmed, INC. | $79.83 | 2020 | |
| Janssen Pharmaceuticals, INC | $70.67 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $62.34 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $58.49 | 2019-2020 | |
| Electromed, INC. | $56.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.63 | 2020-2021 | |
| Portola Pharmaceuticals, LLC | $49.02 | 2019 | |
| Pfizer INC. | $47.99 | 2019-2021 | |
| United Therapeutics Corporation | $36.65 | 2020-2021 | |
| Optinose US, INC. | $28.88 | 2019 | |
| La Jolla Pharmaceutical Company | $24.33 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.13 | 2022 | |
| Alexion Pharmaceuticals, INC. | $23.39 | 2020 | |
| Baxter Healthcare | $23.39 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Nagle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.